Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high-dose GLP-1 receptor agonists and GLP-1 receptor-based co-agonists. - Goldenberg RM; Gilbert JD; Manjoo P; Pedersen SD; Woo VC; Lovshin JA (Obesity reviews : an official journal of the International Association for the Study of Obesity, 2024)